• Blog
  • Human Growth Hormone Market Analysis | 2022-2028

    Human Growth Hormone Market Analysis | 2022-2028

    Human Growth Hormone Market Analysis | 2022-2028
    Report code - SR2543 Delivery - 2 Weeks
    Human Growth Hormone Market Size, Share, Trend, Forecast & Industry Analysis: 2022-202 See more...

    “The Human Growth Hormone Market was estimated at US$ 4.1 billion in 2021 and is expected to grow at a CAGR of 9.18% during 2022-2028 to reach US$ 8.9 billion by 2028.”

    Wish to get a free sample? Register Here

    Market Dynamics

    Introduction

    Human Growth Hormone also known as somatotropin is a peptide hormone secreted by the pituitary gland. It is essential in growth, tissue repair, and metabolism. Thus, it is possible to conclude that HGH plays a role in stimulating the growth of children and adolescents through enhanced protein synthesis and cell proliferation. It assists in the body composition, muscle, and bones as well as metabolism in an adult's body.

    HGH imbalance can therefore cause growth disorders, specifically, its excess leads to gigantism/acromegaly while deficiency causes growth and development problems. It is also clinically applied to the treatment of growth retardation in children, and some hormonal deficiency states in adults.

    Human Growth Hormone Market Report Overview

    Market Size in 2028

    US$ 8.9 billion

    Market Size in 2021

    US$ 4.1 billion

    Market Growth (2022-2028)

    9.18% CAGR

    Base Year of Study

    2021

    Trend Period

    2016-2020

    Forecast Period

    2022-2028

    Market Drivers

    As mentioned by the American Academy of Pediatrics, the deficiency of this hormone in individuals is a rather rare pathological condition, which is characterized in one out of 3,000 to one out of 10,000 children in the United States.

    Presently, HGH is widely utilized as an anti-aging drug among elder people and by athletes and bodybuilders as an anabolic drug. However, as per the USFDA, HGH is categorized as a prescription-only drug and is not approved for any anti-aging or performance-boost uses.

    In addition, increased concerns among the populace about GH deficiency and treatment through human growth hormones are expected to fuel the government and private organizations’ activities for the global market.

    Every year on the third Friday of February, the International Coalition of Organizations Supporting Endocrine Patients (ICOSEP), an internationally affiliated nonprofit charitable organization with headquarters in the United States of America celebrates International Children’s Growth Awareness Day to educate on early identification and Management of growth hormone abnormalities in human beings with particular emphasis on the children.

    However, the high cost of associated therapies that involve HGH and various complications that come with it may act as a restraining factor to the market during the forecast period. For instance, the UPMC Children’s Hospital of Pittsburgh affirms that the side effects of GH hormone therapy include knee, hip, or other joint pains, rashes, swellings or hives, and high blood sugar levels.

    Want to get more details about the drivers? Register Here

    Segments Analysis

    Segmentations

    List of Sub-Segments

    Dominant and Fastest-Growing Segments

    Application Type

    Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature, Prader-Willi Syndrome, Small for Gestational Age, Others

    The Growth Hormone deficiency category dominated the market during the forecast period.

    Distribution Channel Type

    Hospital Pharmacies, Retail Pharmacies, E-Commerce

    The hospital pharmacy segment dominates the market during the forecast period.

    Region Analysis

    North America, Europe, Asia-Pacific, and the Rest of the World

    North America is expected to account for the greatest share during the forecast period.

    By Application Type

    The GH deficiency category accounts for a maximum share during the forecast period.”

    The human growth hormone market is segmented into growth hormone deficiency, turner syndrome, idiopathic short stature, prader-willi syndrome, small for gestational age, and others. The GH deficiency category dominated the market and is projected to continue to do so throughout the forecast period. This is due to increased awareness regarding the early detection and treatment of GH insufficiency in people, as well as the entry of novel medications into the HGH market.

    For example, Ascendis Pharma A/S received an Orphan Designation from the European Commission (EC) in October 2018 for its investigational long-acting GH medication for humans, TransCon HGH, which is recommended for the treatment of pediatric GH deficiency.

    Similarly, Ferring Pharmaceuticals Inc. got USFDA approval in January 2018 for Zomacton (somatropin), a novel recombinant HGH intended for the treatment of adults with GH insufficiency. The GH deficiency category is further subdivided into adult and pediatric GH deficiency, with the latter expected to dominate the market over the projection period due to a rising number of pipeline medications.

    For example, Pfizer Inc. and its partner OPKO Health Inc. stated in October 2019 that their Phase III research of Somatrogon in pre-pubertal children with HGH fulfilled its primary endpoint of non-inferiority to daily somatropin. Turner's syndrome accounted for the second-largest market share in 2021 and is expected to emerge as a profitable category during the projected period. This can be explained by

    By Distribution Channel Type

    “The hospital pharmacy segment dominates the market during the forecast period.”

    The market is segmented into hospital pharmacies, retail pharmacies, and e-commerce. The hospital pharmacy segment held a sizable market share. This large percentage is ascribed to an increase in hospital visits due to increased human awareness of GH insufficiency and therapy. According to the Children's Hospital of Philadelphia (CHOP), growth hormone prescriptions have climbed from 5.1 patients per 10,000 beneficiaries in 2001 to 14.6 patients per 10,000 in 2016.

    Regional Analysis

    North America dominates the market during the forecast period.”

    The human growth hormone market is broken down geographically into areas like North America, Europe, Asia-Pacific, and the Rest of the World. Because of variables such as attractive reimbursement scenarios, established healthcare infrastructure, considerable government initiatives, and expanding healthcare awareness, North America is expected to account for the greatest share.

    Furthermore, the presence of significant firms in the region facilitates access to innovative pharmaceuticals, which benefits the North American market. Pfizer, Inc., Eli Lilly and Company, and Genentech, Inc. are three significant competitors based in the United States that provide a wide range of human GH medicines in the region. 

    Over the forecast period, Asia-Pacific is expected to grow at a rapid pace.

    Key competitors are focusing on attaining a significant market share in potential Asia-Pacific nations such as Japan and China through product approval and launch. For example, in March 2017, Novo Nordisk A/S, a Danish pharmaceutical company, began a phase III clinical trial in Japan for their HGH somapacitan, which is designed for the treatment of adults with growth hormone insufficiency.

    Want to know which region offers the best growth opportunities? Register Here

    Key Players

    The market is highly populated with the presence of several local, regional, and global players. Most of the major players compete in some of the governing factors including price, product offerings, regional presence, etc.

    The following are the key players in the human growth hormone market (arranged alphabetically).

    • Aeterna Zentaris
    • AnkeBio Co. Ltd
    • Eli Lilly and Company
    • EMD Serono Inc.
    • F. Hoffmann-La Roche Ltd
    • Ferring BV
    • GeneScience Pharmaceuticals Co. Ltd
    • Ipsen SA
    • LG Life Sciences
    • Novo Nordisk AS
    • Pfizer Inc.
    • Sandoz International GmbH (Novartis AG)
    • Sinobioway Hygene Biomedicine Co. Ltd
    • Strongbridge Biopharma
    • Teva Pharmaceutical Industries Ltd

    Note: The above list does not necessarily include all the top players in the market.

    Are you the leading player in this market? We would love to include your name. Write to us at sales@stratviewresearch.com

    Report Features

    This report provides market intelligence most comprehensively. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision-making for the existing market players as well as those willing to enter the market.

    What Deliverables Will You Get in this Report?

    Key questions this report answers

    Relevant contents in the report

    How big is the sales opportunity?

    In-depth Analysis of the Human Growth Hormone Market 

    How lucrative is the future?

    The market forecast and trend data and emerging trends

    Which regions offer the best sales opportunities?

    Global, regional, and country-level historical data and forecasts

    Which are the most attractive market segments?

    Market Segment Analysis and Forecast

    Who are the top players and their market positioning?

    Competitive landscape analysis, Market share analysis

    How complex is the business environment?

    Porter’s five forces analysis, PEST analysis, Life cycle analysis

    What are the factors affecting the market?

    Drivers & challenges

    Will I get the information on my specific requirements?

    10% free customization

    Research Methodology

    This report offers high-quality insights and is the outcome of a detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders, and validation and triangulation with Stratview Research’s internal database and statistical tools. 

    More than 1,000 authenticated secondary sources, such as company annual reports, fact books, press releases, journals, investor presentations, white papers, patents, and articles have been leveraged to gather the data. 

    We conducted more than 10 detailed primary interviews with the market players across the value chain in all four regions and with industry experts to obtain both qualitative and quantitative insights.

    Customization Options

    With this detailed report, Stratview Research offers one of the following free customization options to our respectable clients:

    Company Profiling

    • Detailed profiling of additional market players (up to 3 players).
    • SWOT analysis of key players (up to 3 players).

    Market Segmentation

    • Current market segmentation of any one of the product types by application type.  

    Competitive Benchmarking

    • Benchmarking of key players on the following parameters: Product portfolio, geographical reach, regional presence, and strategic alliances.

    Custom Research: Stratview Research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to sales@stratviewresearch.com

    Recent Market News

    Several businesses are working on long-acting human growth hormones. Mergers, partnerships, as well as acquisitions are significant methods used by the market's leading players to extend their geographical scope and provide access to their products. For example,

    • Novo Nordisk A/S, Pfizer, Inc., Eli Lilly and Company, Sandoz International GmbH (Novartis AG), Merck KGaA, Genentech, Inc. (Roche), Ferring Pharmaceuticals, Teva Pharmaceutical Industries, Ltd, and Ipsen are some of the market's prominent participants. 

    • In October 2018, Novo Nordisk and Strongbridge Biopharma agreed to buy the rights to MACRILEN in the United States and Canada. MACRILEN (macimorelin) is the first and only FDA-approved oral medication for the diagnosis of adult growth hormone insufficiency.

    Several investments/guidelines in the industry have been directed in recent years, which would boost the overall market. Some of them are:

    • The human growth hormones market is likely to be driven by a robust product pipeline and extensive R&D initiatives for the development of innovative growth hormone therapies. In September 2018, Novo Nordisk presented Phase II clinical trial data for Somapacitan, an experimental GH medication recommended for treating pediatric growth hormone insufficiency.

    • Furthermore, Ascendis Pharma A/S announced Phase III clinical trial findings for their TransCon HGH, indicated for juvenile growth hormone insufficiency, in May 2019.

    Teva Pharmaceutical Industries, Ltd., OPKO Health, Inc., Eli Lilly and Company, Ferring Pharmaceuticals, Sanofi S.A., and LG Life Sciences are also engaging in R&D initiatives to develop innovative human growth hormone therapy.

    Frequently Asked Questions (FAQs)

    Human Growth Hormone also known as somatotropin is a peptide hormone secreted by the pituitary gland. It is essential in growth, tissue repair, and metabolism. Thus, it is possible to conclude that HGH plays a role in stimulating the growth of children and adolescents through enhanced protein synthesis and cell proliferation. It assists in the body composition, muscle, and bones as well as metabolism in an adult's body. HGH imbalance can therefore cause growth disorders, specifically, its excess leads to gigantism/acromegaly while deficiency causes growth and development problems. It is also clinically applied to the treatment of growth retardation in children, and some hormonal deficiency states in adults.

    The market is expected to grow at a CAGR of 9.18% during 2022-2028.

    The major players in the human growth hormone market are AnkeBio Co. Ltd, EMD Serono Inc., F. Hoffmann-La Roche Ltd, Ferring BV, Ipsen SA, Eli Lilly and Company, Novo Nordisk AS, Pfizer Inc., Teva Pharmaceutical Industries Ltd, Sandoz International GmbH (Novartis AG), Strongbridge Biopharma, GeneScience Pharmaceuticals Co. Ltd, Sinobioway Hygene Biomedicine Co. Ltd, Aeterna Zentaris, LG Life Sciences.

    The human growth hormone market size is projected to reach US$ 8.9 billion by 2028.

    North America is expected to be dominant in the market during the forecast period.

    The growth hormone deficiency category dominated the market during the forecast period.